Cabergoline 0.5 mg Tablet (Cabergoline 0.5 mg)

Stop Prolactin Side Effects Cold

Cabergoline (Dostinex) is a dopamine agonist used to lower prolactin levels in the body. For bodybuilders using 19-Nor compounds like Trenbolone and Deca Durabolin, rising prolactin can cause serious side effects, including sexual dysfunction ("Deca Dick") and prolactin-induced gynecomastia.

Cabergoline is the most effective way to combat these issues, restoring libido and preventing unwanted side effects quickly and effectively.

Key Benefits:

• Lowers Prolactin: Essential for users of Trenbolone and Deca.
• Restores Libido: Fixes sexual dysfunction caused by high prolactin.
• Prevents Lactation Gyno: Stops the development of prolactin-based gynecomastia.
• improves Mood: Dopamine agonist effects can improve mood and well-being.

Dosage:

• Typical Dose: 0.25mg to 0.5mg twice per week.
• Note: Cabergoline is very potent. Do not overdose. Start low.

1. Description — Clinical summary

Cabergoline (tablet: 0.5 mg cabergoline per tablet) is an ergoline-derived, long-acting dopamine D2 receptor agonist. It is principally used to treat hyperprolactinemia (prolactin-secreting pituitary adenomas and idiopathic hyperprolactinemia) by lowering serum prolactin and reducing tumor size in many patients. It has also been used off‑label for short-term lactation suppression and historically at higher doses in Parkinson’s disease, although higher doses carry increased risk of cardiac valvular and fibrotic complications.

Typical clinical effects:

• Rapid reduction of serum prolactin (often within days; normalization usually within weeks).
• Reduction in prolactinoma size in many patients.
• Long plasma half-life allows infrequent dosing (commonly twice weekly for endocrine indications).

This guide is educational and not a substitute for individualized medical advice. Treatment decisions, dose adjustments, and monitoring should be made by a qualified prescriber.

2. How does Cabergoline 0.5 mg work? — Mechanism of action

Cabergoline is a selective dopamine D2 receptor agonist. Mechanisms relevant to its clinical effects:

• Activation of D2 receptors on anterior pituitary lactotroph cells inhibits adenylate cyclase activity and decreases prolactin synthesis and secretion.
• The resulting fall in circulating prolactin relieves hyperprolactinemia-related symptoms (galactorrhea, hypogonadism, menstrual irregularities, infertility) and may reduce the size of prolactin-secreting pituitary adenomas.
• Cabergoline is an ergoline derivative and has affinity for other monoaminergic receptors; agonism at 5‑HT2B receptors has been implicated in ergot-associated fibrotic valvular heart disease seen with some dopamine agonists at higher cumulative doses.

Pharmacokinetics relevant to dosing:

• Long elimination half-life (many tens of hours) supports infrequent dosing (typically twice weekly in endocrine uses).
• Oral bioavailability is sufficient for systemic endocrine effects.

3. Dosage — Medical and varying usage guidelines

Dosing must be individualized for indication, patient response, and tolerance. The regimens below summarize commonly used approaches; always follow the prescribing clinician’s instructions.

General principles

• Start low and titrate based on prolactin levels, clinical response, and side effects.
• Take with food if nausea occurs (may reduce GI intolerance).
• Monitor blood pressure (risk of orthostatic hypotension), mental state and for signs of valvular heart disease with long-term or high-dose therapy.

Typical regimens (examples only)

• Hyperprolactinemia (most common endocrine use)
  • Typical initial: 0.25 mg twice weekly (for example, Monday and Thursday) — total 0.5 mg/week.
  • Many patients are maintained on 0.5 mg twice weekly (1 mg/week).
  • If necessary, dosage may be increased gradually (e.g., to 1 mg twice weekly or other regimens) until prolactin normalizes and symptoms resolve. Dose escalation should be conservative and under specialist guidance.
• Lactation suppression (off-label/varies by practice)
  • Some regimens reported a single 1 mg dose immediately postpartum; others use short courses. Use for lactation suppression should be considered carefully with attention to contraindications and alternatives.
• Parkinson’s disease (historical/high-dose use)
  • Doses used in Parkinson’s are substantially higher (often mg/day rather than mg/week) and carry an increased risk of valvular heart disease and fibrotic complications. Use in Parkinson’s requires specialist oversight and echocardiographic monitoring; many guidelines restrict or avoid high-dose ergot-derived dopamine agonists.

Duration and monitoring

• For hyperprolactinemia, treatment duration is individualized; many patients continue long-term if prolactinoma persists or recurs when therapy is stopped.
• Measure serum prolactin to guide therapy; evaluate clinical response.
• For long-term or high cumulative doses, periodic cardiac evaluation (echocardiography) is recommended by many clinicians to screen for valvular regurgitation.

Important safety note

• Do not adjust dose or stop therapy without consulting the prescribing clinician. If you experience severe side effects (e.g., new shortness of breath, chest pain, fainting, severe swelling, new psychiatric symptoms), seek medical attention promptly.

4. Side effects — Common and rare adverse effects

Common (usually mild to moderate)

• Nausea, vomiting
• Headache
• Dizziness, lightheadedness, orthostatic hypotension (postural drop in blood pressure)
• Fatigue, somnolence
• Constipation, abdominal pain
• Nasal congestion, dyspepsia

Psychiatric and neurological

• Insomnia, anxiety, depression
• Hallucinations, confusion, agitation (more likely in older patients or at higher doses)
• Excessive daytime sleepiness; sudden onset sleep episodes reported
• Impulse control disorders (rare but important): pathological gambling, hypersexuality, compulsive shopping, binge eating — patients and families should be warned and monitored

Serious but less common/rare

• Cardiac valvular disease (valvular regurgitation and fibrotic changes): risk increases with higher cumulative doses and prolonged therapy; echocardiographic monitoring is often advised for long-term/higher-dose use
• Fibrotic reactions (pulmonary fibrosis, pleural effusion, retroperitoneal fibrosis) — rare but reported with ergot derivatives
• Severe hypotension or syncope
• Psychosis or severe psychiatric disturbances
• Hypersensitivity reactions (rare)

Drug interactions and exacerbating factors

• Dopamine antagonists (e.g., many antipsychotics, metoclopramide) antagonize cabergoline’s effects.
• Concomitant antihypertensive therapy may increase risk of symptomatic hypotension.
• Use caution with other drugs that affect dopaminergic or serotonergic systems.
• Patients with a history of psychotic disorders or uncontrolled hypertension generally require specialist oversight or avoidance.

Pregnancy and breastfeeding

• If pregnancy is planned or occurs, consult a specialist. Management of prolactinomas in pregnancy requires individualized assessment. Some clinicians prefer agents with larger safety databases in pregnancy (e.g., bromocriptine); others have used cabergoline in early pregnancy when indicated. Cabergoline suppresses lactation and therefore is not used when breastfeeding is desired.

Report any new or concerning symptoms to the prescriber promptly.

5. Storage — How to store cabergoline 0.5 mg tablets

• Store at room temperature, typically 15–30 °C (59–86 °F), unless the product label specifies otherwise.
• Keep tablets in their original container to protect from moisture and light.
• Keep tightly closed and out of reach of children and pets.
• Do not freeze.
• Dispose of expired or unused medication according to local regulations — do not flush down the toilet. Ask a pharmacist about take-back programs if available.

Additional practical points

• Because of the risk of orthostatic hypotension, patients should rise slowly from sitting or lying positions until they know how cabergoline affects them.
• Carry out baseline assessment (serum prolactin, pregnancy test if applicable, clinical cardiac assessment) and schedule follow-up prolactin measurements to guide therapy.
• For long-term/high-dose therapy, consider periodic echocardiography and regular clinical review for psychiatric or impulse-control symptoms.

If you need a printable dosing summary, monitoring checklist, or references to guideline statements for treating hyperprolactinemia and cabergoline safety monitoring, tell me which format you prefer and I will provide that.